Abstract
A promising new class of proteins for therapeutic purposes makes an entrance; small in size, with multiple low-affinity binding sites for their targets and many disulfide bonds, they are easy to produce and almost completely nonimmunogenic and ready for a clinical trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

Katie Ris
References
Silverman, J. et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 23, 1556–1561 (2005).
Rights and permissions
About this article
Cite this article
Rusk, N. Strength in numbers. Nat Methods 3, 4 (2006). https://doi.org/10.1038/nmeth0106-4a
Issue date:
DOI: https://doi.org/10.1038/nmeth0106-4a